EUVIMEDEUVIMED entdecken
Crossref

SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer

Hao-Jie Chen, Ming-Ming Yu, Jia-Cheng Huang, Fu-Ying Lan, Hai-Hong Liao, Zi-Han Xu, Yong-Jiang Yu, Yi-Chen Huang, Fang Chen

Cancer Letters · 2024-08 · 597 · 217070

DOI: 10.1016/j.canlet.2024.217070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Hao-Jie Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urolog…. Hauptthemen laut MEDLINE: Benzamides, Drug Resistance, Neoplasm, Nitriles, Phenylthiohydantoin. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen receptor signaling inhibitor (ARSI) enzalutamide (Enz) has shown critical efficacy in the treatment of advanced prostate cancer (PCa). However, the development of drug resistance is a significant factor contributing to mortality in PCa patients. We aimed to explore the key mechanisms of Enz-resistance. Through analysis of GEO databases, we identified SLC4A4 as a novel driver in Enz resistance. Long-term Enz treatment leads to the up-regulation of SLC4A4, which in turn mediates P53 lactylation via the NF-κB/STAT3/SLC4A4 axis, ultimately leading to the development of Enz resistance and progression of PCa. SLC4A4 knockdown overcomes Enz resistance both in vitro and in vivo. Hence, our results suggest that targeting SLC4A4 could be a promising therapeutic strategy for Enz resistance. STATEMENT OF SIGNIFICANCE: SLC4A4 is a novel driver of enzalutamide resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesDrug Resistance, NeoplasmNitrilesPhenylthiohydantoinProstatic NeoplasmsSodium-Bicarbonate SymportersAnimalsHumansMaleMiceCell Line, TumorGene Expression Regulation, NeoplasticNF-kappa BSignal TransductionSTAT3 Transcription FactorTumor Suppressor Protein p53Up-RegulationXenograft Model Antitumor Assays

Stichwörter der Autor:innen

EnzalutamidePCaProstate cancerResistanceSLC4A4

Substanzen

BenzamidesenzalutamideNF-kappa BNitrilesPhenylthiohydantoinSTAT3 protein, humanSTAT3 Transcription FactorTP53 protein, humanTumor Suppressor Protein p53SLC4A4 protein, human

Autor:innen und Institutionen

  • Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University,…
  • Department of Ultrasound in Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
  • Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
  • Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
  • Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China. Electronic address: yuyongjiang@xinhuamed.com.cn.
  • Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China. Electronic address: drhuangyichen@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, H. J., Yu, M. M., Huang, J. C., Lan, F. Y., Liao, H. H., Xu, Z. H., Yu, Y. J., Huang, Y. C., & Chen, F. (2024). SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Letters, 597, 217070. https://doi.org/10.1016/j.canlet.2024.217070

Vancouver

Chen HJ, Yu MM, Huang JC, Lan FY, Liao HH, Xu ZH, et al. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Letters. 2024;597:217070. doi:10.1016/j.canlet.2024.217070

BibTeX
@article{Chen2024,
  author = {Chen, Hao-Jie and Yu, Ming-Ming and Huang, Jia-Cheng and Lan, Fu-Ying and Liao, Hai-Hong and Xu, Zi-Han and Yu, Yong-Jiang and Huang, Yi-Chen and Chen, Fang},
  title = {SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {597},
  pages = {217070},
  doi = {10.1016/j.canlet.2024.217070}
}
Kostenlos starten →